WO2006061233A1 - The use of medicament 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide - Google Patents

The use of medicament 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide Download PDF

Info

Publication number
WO2006061233A1
WO2006061233A1 PCT/EP2005/013205 EP2005013205W WO2006061233A1 WO 2006061233 A1 WO2006061233 A1 WO 2006061233A1 EP 2005013205 W EP2005013205 W EP 2005013205W WO 2006061233 A1 WO2006061233 A1 WO 2006061233A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
compound
pharmaceutically acceptable
piperidine
methyl
Prior art date
Application number
PCT/EP2005/013205
Other languages
French (fr)
Inventor
David Patrick Brooks
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to JP2007544826A priority Critical patent/JP2008523015A/en
Priority to EP05826659A priority patent/EP1824487A1/en
Publication of WO2006061233A1 publication Critical patent/WO2006061233A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to the use of a piperidine derivative and pharmaceutically acceptable salts or solvates thereof in the treatment or prevention of overactive bladder 5
  • the present invention relates to the use of 4-(S)-(4-Acetyl-piperazin-1-yl)-2- (R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl- phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts thereof.
  • a 0 particular preferred compound described therein is 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)- (4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid (hereinafter the compound ).
  • Suitable pharmaceutically acceptable salts of the compound include acid addition salts formed with pharmaceutically acceptable organic or inorganic acids, for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or p-toluenesulphonates), phosphates, acetates, citrates, 0 succinates, tartrates, fumarates and maleates.
  • pharmaceutically acceptable organic or inorganic acids for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or p-toluenesulphonates), phosphates, acetates, citrates, 0 succinates, tartrates, fumarates and maleates.
  • a preferred salt of the compound is hydrochloride, methanesulphonate, sulphate or p- toluensulphonate.
  • a particularly preferred salt of the compound is methanesulphonate.
  • the compound or salts or solvates thereof are described in the aforementioned specifications as antagonists of tachykinins, including substance P and other neurokinins, both in vitro and in vivo and are thus of use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.
  • the compound or salts or solvates thereof are useful in the treatment of CNS disorders.
  • the compound is of particular use in the treatment of depressive states, anxiety panic disorders, sleep disorders including dysomnia, insomnia, sleep apnea, narcolepsy, and circadian admiric disorders, Sleep Disorder Due to a General Medical 5 Condition, in particular sleep disturbances associated with such diseases as neurological disorders; neuropathic pain, restless leg syndrome, heart and lung diseases; and Substance-Induced Sleep Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and Mixed Type; sleep apnea and jet-lag syndrome; emesis, including chemotherapy induced emesis postoperative nausea and vomiting, traumatic pain, postoperative pain, neuropathic pain, fibromyalgia.
  • the compound may be of value in the treatment of sexual dysfunctions including Sexual Desire Disorders such as Hypoactive Sexual Desire Disorder and sexual Aversion Disorder sexual arousal disorders such as Female sexual Arousal Disorder and Male Erectile Disorder orgasmic disorders such as Female Orgasmic Disorder, Male Orgasmic Disorder and Premature Ejaculation sexual pain disorder such as Dyspareunia and Vaginismus, sexual Dysfunction Not Otherwise Specified; paraphilias such as Exhibitionism, Fetishism, Frotteurism, Pedophilia, sexual Masochism, sexual Sadism Transvestic Fetishism, Voyeurism and Paraphilia Not Otherwise Specified gender identity disorders such as Gender Identity Disorder in Children and Gender Identity Disorder in Adolescents or Adults and Sexual Disorder Not Otherwise Specified.
  • Sexual Desire Disorders such as Hypoactive Sexual Desire Disorder and Sexual Aversion Disorder sexual arousal disorders such as Female sexual Arousal Disorder and Male Erectile Disorder orgasmic disorders such as Female Orgasmic Disorder
  • the compound may also be of value in the treatment of a condition of the above conditions.
  • Overactive bladder is a term for a syndrome that encompasses urinary frequency, with or without urge incontinence, generally but not necessarily combined with pollacisuria and nocturia. Overactive bladder is also characterised by involuntary detrusor contractions which are either triggered by provocation or occur spontaneously. If the detrusor hyperactivity observed is based on neurological causes (e. g. Parkinson's disease, apoplexy, some forms of multiple sclerosis, spinal cord injury or the cross section of the bone marrow) it is known as neurogenic detrusor hyperactivity. If no clear cause can be detected this is known as idiopathic detrusor hyperactivity. In addition, detrusor hyperactivity may be associated with anatomical changes in the lower urinary tract, for example, in patients with bladder outlet obstruction (an enlargement of the prostate gland in males).
  • the invention provides a method of treatment of overactive bladder which comprises administering to a human or animal subject an effective amount of the compound or a pharmaceutically acceptable salt or solvate thereof.
  • the compound may be used prophylactically and references in this specification to treatment include prophylactic treatment as well as the alleviation of acute symptoms. Accordingly, the invention also provides a pharmaceutical composition which comprises the compound or pharmaceutically acceptable salts or solvates thereof for the treatment or prevention of overactive bladder.
  • the invention provides the use of the compound or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment of overactive bladder.
  • the invention provides the use of the compound or a pharmaceutically acceptable salt or solvate thereof, for the treatment of overactive bladder.
  • compositions for use in accordance with the present invention may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients.
  • the compound and its pharmaceutically acceptable salts or solvates may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycolate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycolate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • the preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • the composition may take the form of tablets or formulated in conventional manner.
  • the compound of the invention and its pharmaceutically acceptable salts or solvates may be formulated for parenteral administration by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the compound of the invention and its pharmaceutically acceptable salts or solvates may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or nonaqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
  • the compound of the invention and its pharmaceutically acceptable salts or solvates may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compound of the invention and its pharmaceutically acceptable salts or solvates may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compound of the invention and its pharmaceutically acceptable salts or solvates may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
  • a proposed dose of the compound of the invention is 1 to about 10OOmg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also depend on the route of administration and the particular compound selected.
  • a daily dose will typically be in the range of 1 to about 200 mg, preferably 40 to 150 mg per day.
  • a daily dose will typically be within the range 1 to 300 mg e.g 1 to 100 mg.
  • the compound and pharmaceutically acceptable salts thereof may be prepared by the process described in international patent application WO 02/ 32867 which is incorporated herein by reference.
  • Compound A The effects of the compound as methansulphonate salt ( hereinafter Compound A) on the time to void (void interval) were evaluated in normal female guinea pigs and under conditions of bladder irritation with acetic acid in the anaesthetized female guinea pig and cat.

Abstract

The present invention relates to a new medical use 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing it, in the treatment of overactive bladder.

Description

4- (S) - (4-ACETYL-PIPERAZIN-I-YL) -2- (R) - (4-FLUORO-2-METHYL-PHENYL) -PIPERIDINΞ-l-CA.
RBOXILIC
ACID, [1- (R) - (3, 5-BIS-TRIFLUOROMETHYL-PHENYL) -ETHYL] -METHYLAMIDE
This invention relates to the use of a piperidine derivative and pharmaceutically acceptable salts or solvates thereof in the treatment or prevention of overactive bladder 5 Particularly, the present invention relates to the use of 4-(S)-(4-Acetyl-piperazin-1-yl)-2- (R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl- phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts thereof.
International patent application WO 02/32867 describes novel piperidine derivatives. A 0 particular preferred compound described therein is 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)- (4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid (hereinafter the compound ).
The aforementioned specification also disclose pharmaceutically acceptable salts or solvates, e.g hydrates of the compound. 5
Suitable pharmaceutically acceptable salts of the compound include acid addition salts formed with pharmaceutically acceptable organic or inorganic acids, for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or p-toluenesulphonates), phosphates, acetates, citrates, 0 succinates, tartrates, fumarates and maleates.
A preferred salt of the compound is hydrochloride, methanesulphonate, sulphate or p- toluensulphonate.
A particularly preferred salt of the compound is methanesulphonate.
5 The compound or salts or solvates thereof are described in the aforementioned specifications as antagonists of tachykinins, including substance P and other neurokinins, both in vitro and in vivo and are thus of use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.
0 More particularly, the compound or salts or solvates thereof are useful in the treatment of CNS disorders.
Thus for example the compound is of particular use in the treatment of depressive states, anxiety panic disorders, sleep disorders including dysomnia, insomnia, sleep apnea, narcolepsy, and circadian ritmic disorders, Sleep Disorder Due to a General Medical 5 Condition, in particular sleep disturbances associated with such diseases as neurological disorders; neuropathic pain, restless leg syndrome, heart and lung diseases; and Substance-Induced Sleep Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and Mixed Type; sleep apnea and jet-lag syndrome; emesis, including chemotherapy induced emesis postoperative nausea and vomiting, traumatic pain, postoperative pain, neuropathic pain, fibromyalgia.
Furthermore the compound may be of value in the treatment of Sexual dysfunctions including Sexual Desire Disorders such as Hypoactive Sexual Desire Disorder and Sexual Aversion Disorder sexual arousal disorders such as Female Sexual Arousal Disorder and Male Erectile Disorder orgasmic disorders such as Female Orgasmic Disorder, Male Orgasmic Disorder and Premature Ejaculation sexual pain disorder such as Dyspareunia and Vaginismus, Sexual Dysfunction Not Otherwise Specified; paraphilias such as Exhibitionism, Fetishism, Frotteurism, Pedophilia, Sexual Masochism, Sexual Sadism Transvestic Fetishism, Voyeurism and Paraphilia Not Otherwise Specified gender identity disorders such as Gender Identity Disorder in Children and Gender Identity Disorder in Adolescents or Adults and Sexual Disorder Not Otherwise Specified.
The compound may also be of value in the treatment of a condition of the above conditions.
We have now surprisingly found that the compound or pharmaceutically acceptable salts or solvates thereof are also useful in the treatment of overactive bladder .
Overactive bladder is a term for a syndrome that encompasses urinary frequency, with or without urge incontinence, generally but not necessarily combined with pollacisuria and nocturia. Overactive bladder is also characterised by involuntary detrusor contractions which are either triggered by provocation or occur spontaneously. If the detrusor hyperactivity observed is based on neurological causes (e. g. Parkinson's disease, apoplexy, some forms of multiple sclerosis, spinal cord injury or the cross section of the bone marrow) it is known as neurogenic detrusor hyperactivity. If no clear cause can be detected this is known as idiopathic detrusor hyperactivity. In addition, detrusor hyperactivity may be associated with anatomical changes in the lower urinary tract, for example, in patients with bladder outlet obstruction (an enlargement of the prostate gland in males).
Accordingly, the invention provides a method of treatment of overactive bladder which comprises administering to a human or animal subject an effective amount of the compound or a pharmaceutically acceptable salt or solvate thereof.
It will be appreciated that the compound may be used prophylactically and references in this specification to treatment include prophylactic treatment as well as the alleviation of acute symptoms. Accordingly, the invention also provides a pharmaceutical composition which comprises the compound or pharmaceutically acceptable salts or solvates thereof for the treatment or prevention of overactive bladder.
In a yet further aspect, the invention provides the use of the compound or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment of overactive bladder.
In a yet further aspect, the invention provides the use of the compound or a pharmaceutically acceptable salt or solvate thereof, for the treatment of overactive bladder.
Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients.
Thus, the compound and its pharmaceutically acceptable salts or solvates may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycolate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
Preparations for oral administration may be suitably formulated to give controlled release of the active compound. For buccal administration the composition may take the form of tablets or formulated in conventional manner.
The compound of the invention and its pharmaceutically acceptable salts or solvates may be formulated for parenteral administration by bolus injection or continuous infusion.
Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
The compound of the invention and its pharmaceutically acceptable salts or solvates may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or nonaqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
The compound of the invention and its pharmaceutically acceptable salts or solvates may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
The compound of the invention and its pharmaceutically acceptable salts or solvates may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
For intranasal administration, the compound of the invention and its pharmaceutically acceptable salts or solvates may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device. A proposed dose of the compound of the invention is 1 to about 10OOmg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also depend on the route of administration and the particular compound selected.
Thus, for parenteral administration a daily dose will typically be in the range of 1 to about 200 mg, preferably 40 to 150 mg per day. For oral administration a daily dose will typically be within the range 1 to 300 mg e.g 1 to 100 mg.
The compound and pharmaceutically acceptable salts thereof may be prepared by the process described in international patent application WO 02/ 32867 which is incorporated herein by reference.
Pharmacological Activity Micturition parameters in the conscious guinea pig and acetic acid-evoked bladder instability in the anaesthetized guinea pig and cat
The effects of the compound as methansulphonate salt ( hereinafter Compound A) on the time to void (void interval) were evaluated in normal female guinea pigs and under conditions of bladder irritation with acetic acid in the anaesthetized female guinea pig and cat. In the conscious normal guinea pig Compound A significantly increased void interval by 63.6 ± 27.7 % (n = 5) and 48.7 ± 18.4 % (n = 7) following 1 and 3 mg/kg intraduodenal (i.d.) administration, respectively. In acetic acid-evoked bladder irritation in the anaesthetized guinea pig, characterized by an increase in the frequency of voiding, Compound A significantly increased void interval by 42.7 ± 4.3 % (n = 3), 137 ± 38.4 % (n = 4) and 93.2 ± 19.4 % (n = 4), following 1 , 3 and 10 mg/kg i.d. administration, respectively. In the anaesthetized cat, Compound A significantly attenuated bladder irritation evoked by acetic acid (3 mg/kg Lv.; n = 4).

Claims

1. Use of 4-(S)-(4-Acetyl-piperazin-1~yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine- 1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts or solvates thereof in the preparation of a medicament for use in the treatment of overactive bladder.
.
2. Use of a 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine- 1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts or solvates thereof for use in the treatment of overactive bladder.
3. Use according to claim 1 or claim 2 wherein the pharmaceutically acceptable salt of the compound is methansulphonate.
4. A method for the treatment of overactive bladder comprising administering to that person an effective amount of the compound or pharmaceutically acceptable salts or solvates thereof.
5. Method for the treatment according to claim 4 wherein the pharmaceutically acceptable salt of the compound is methansulphonate.
PCT/EP2005/013205 2004-12-08 2005-12-07 The use of medicament 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide WO2006061233A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007544826A JP2008523015A (en) 2004-12-08 2005-12-07 Drug 4- (S)-(4-acetyl-piperazin-1-yl) -2- (R)-(4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid, [1- (R) Use of-(3,5-bis-trifluoromethyl-phenyl) -ethyl] -methylamide
EP05826659A EP1824487A1 (en) 2004-12-08 2005-12-07 The use of 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxilic acid, [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide for the treatment of overactive bladder

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0426942.9A GB0426942D0 (en) 2004-12-08 2004-12-08 Medicament
GB0426942.9 2004-12-08

Publications (1)

Publication Number Publication Date
WO2006061233A1 true WO2006061233A1 (en) 2006-06-15

Family

ID=34073401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/013205 WO2006061233A1 (en) 2004-12-08 2005-12-07 The use of medicament 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide

Country Status (4)

Country Link
EP (1) EP1824487A1 (en)
JP (1) JP2008523015A (en)
GB (1) GB0426942D0 (en)
WO (1) WO2006061233A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065746A2 (en) * 2008-12-03 2010-06-10 Auspex Pharmaceutical, Inc Piperazine modulators of nk-1 receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032867A1 (en) * 2000-10-17 2002-04-25 Glaxo Group Limited Chemical compounds
WO2004091616A1 (en) * 2003-04-17 2004-10-28 Glaxo Group Limited Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032867A1 (en) * 2000-10-17 2002-04-25 Glaxo Group Limited Chemical compounds
WO2004091616A1 (en) * 2003-04-17 2004-10-28 Glaxo Group Limited Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHEL M C: "NEUE PHARMAKOLOGISCHE THERAPIEKONZEPTE BEI UEBERAKTIVER BLASE NEW PHARMACOLOGIAL TREATMENT CONCEPTS FOR OVERACTIVE BLADDER", UROLOGE AUSGABE A, SPRINGER, BERLIN, DE, vol. 42, no. 6, June 2003 (2003-06-01), pages 807 - 811, XP001188935, ISSN: 0340-2592 *
SELLERS DONNA J ET AL: "Potential therapeutic targets for treatment of the overactive bladder", WORLD JOURNAL OF UROLOGY, SPRINGER INTERNATIONAL, DE, vol. 19, no. 5, 2001, pages 307 - 311, XP002971377, ISSN: 0724-4983 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065746A2 (en) * 2008-12-03 2010-06-10 Auspex Pharmaceutical, Inc Piperazine modulators of nk-1 receptors
WO2010065746A3 (en) * 2008-12-03 2010-10-14 Auspex Pharmaceutical, Inc Piperazine modulators of nk-1 receptors

Also Published As

Publication number Publication date
JP2008523015A (en) 2008-07-03
GB0426942D0 (en) 2005-01-12
EP1824487A1 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
US8658683B2 (en) Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
JPH05507731A (en) Pharmaceutical compositions for the treatment of substance abuse disorders
US20020035057A1 (en) Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions
US20090239881A1 (en) Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments
JP2002523366A (en) Compositions containing dopamine reuptake inhibitors and methods of using the same
KR20130065650A (en) Methods of improving quality of sleep
BG107217A (en) Apomorphine derivatives and method for their use
TWI419689B (en) Drug combinations for the treatment of sialorrhoea
KR101049694B1 (en) Alpha-aminoamide derivatives useful as antimigraine agents
KR20010032009A (en) Use of mirtazapine for treating sllep apneas
EP1740174A1 (en) Derivatives of aryl(or heteroaryl) azolylcarbinols for the treatment of enuresis
KR20040030788A (en) Derivatives of aryl(or heteroaryl) azolylcarbinols for the treatment of urinary incontinence
KR20030077538A (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US7396854B2 (en) Use of serotonergic compound for a method of treatment of hot flushes in post-menopausal women
AU2007259224A1 (en) Use of a P38 kinase inhibitor for treating psychiatric disorders
JP4620329B2 (en) Use of melatonin in the manufacture of drugs for attention deficit hyperactivity disorder
CZ285633B6 (en) Use of indole derivatives for preparing medicaments
WO2006061233A1 (en) The use of medicament 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide
US20120238616A1 (en) Methods and compositions for treating sleep-related breathing disorders
US20120309838A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of obsessive-compulsive disorder (ocd)
JP2005526695A (en) Methods for producing and using 2-hydroxy derivatives of sibutramine and its metabolites
KR20010024768A (en) New Use of Local Anaesthetics Against Vascular Headaches
JP2015520145A (en) Treatment of respiratory depression
KR20240053061A (en) Methods and compositions for treating sleep apnea
KR20140130695A (en) (1r,4r)-6'-FLUORO-(N-METHYL- OR N,N-DIMETHYL-)-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO-[CYCLOHEXANE-1,1'-PYRANO[3,4,b]INDOL]-4-AMINE FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007544826

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005826659

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005826659

Country of ref document: EP